To the full analysis
Lyell Immunopharma stock: growth
LYELLyell Immunopharma reported $36K in revenue for fiscal 2025, down 41% on the prior year, down 65.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
−38.4%
per year from 2019 to 2025, per share −41.6%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2019 | |
|---|---|---|
| Revenue | −65.9% | −38.4% |
| Revenue per share | −68.0% | −41.6% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2019 | $657K | −$129.38M | $23.43M |
| 2020 | $7.76M | −$204.47M | −$212.36M |
| 2021 | $10.65M | −$250.22M | −$191.75M |
| 2022 | $84.68M | −$183.12M | −$193.83M |
| 2023 | $130K | −$234.63M | −$166.38M |
| 2024 | $61K | −$342.99M | −$162.86M |
| 2025 | $36K | −$274.45M | −$150.8M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.